Inhibikase Therapeutics Inc. (IKT)
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 1.94 0.00%
IKT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $270.70M
- EPS (TTM)
- -$0.43
- Dividend yield
- None
- 52-week range
- 1.33 – 2.61
- Day range
- 1.93 – 2.00
- Volume / Avg
- 436.01K / 665.95K
- Beta
- —
- Shares outstanding
- 139.54M
- Next earnings
- Nov 13, 2026
52-week range
IKT stock today
Inhibikase Therapeutics (IKT) closed at $1.94 on Oct 7, down 2.02% (-$0.04), versus the S&P 500's 0.22% decline. At this level, IKT sits in the middle of its 52-week range of $1.33 to $2.61: 25.7% below the high and 45.9% above the low. Inhibikase Therapeutics has posted a net loss over the last twelve months (EPS of -$0.43), so its P/E ratio is not meaningful.
Inhibikase Therapeutics's next earnings report is expected on Nov 13, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Inhibikase Therapeutics
Company profile- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year
- 2020
Earnings
Earnings history- Next report
- Nov 13, 2026
Inhibikase Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XFORX4 Pharmaceuticals Inc. | 2.81 | +1.44% | $278.60M | vs IKT |
| LXEOLexeo Therapeutics Inc. | 3.31 | +0.30% | $271.71M | vs IKT |
| SABSSAB Biotherapeutics Inc. | 2.88 | -1.71% | $262.04M | vs IKT |
| PALIPalisade Bio Inc. | 1.48 | -0.67% | $257.92M | vs IKT |
| FATEFate Therapeutics Inc. | 2.15 | -6.11% | $257.61M | vs IKT |
| SRZNSurrozen Inc. | 25.15 | -4.65% | $295.54M | vs IKT |
| STROSutro Biopharma Inc. | 14.66 | +1.45% | $243.08M | vs IKT |
| LCTXLineage Cell Therapeutics Inc. | 0.9513 | +1.43% | $240.59M | vs IKT |
Indexes, lists and sector
Largest Health Care stocks
Inhibikase Therapeutics stock FAQ
What is Inhibikase Therapeutics's stock price today?
IKT last traded at $1.94 as of Oct 7, 4:00 PM EDT, down 2.02% on the day. Prices are delayed at least 15 minutes.
When is Inhibikase Therapeutics's next earnings date?
Inhibikase Therapeutics is expected to report earnings on Friday, November 13, 2026.
What is the IKT 52-week high?
The 52-week high for IKT is $2.61 and the 52-week low is $1.33. The stock is currently 25.7% below its high.